STING (or SRC) Like an ICB: Priming the Immune Response in Pancreatic Cancer.

Abstract

Pancreatic adenocarcinoma is associated with a poor prognosis and resistance to immune checkpoint blockade. Zhang and colleagues demonstrate that inhibiting DNA repair by pharmacologic blockade or siRNA silencing of ataxia telangiectasia mutated (ATM) increases type I IFN release via a cGAS/STING-independent, SRC-dependent mechanism in models of pancreatic cancer. Furthermore, combining ATM inhibition and radiotherapy amplifies type I IFN signaling, increases programmed death ligand 1 (PD-L1) expression, tumor CD8⁺ T cells, and proinflammatory tumor macrophages. Finally, the combination of ATM silencing, radiotherapy, and PD-L1 blockade markedly improves <i>in vivo</i> murine tumor responses, supporting further investigation of this promising approach in pancreatic adenocarcinoma.<i>See related article by Zhang et al., p. 3940</i>.